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Background and Methods: Measurement of whole blood tacrolimus level by high performance liquid
chromatography tandem mass spectrometry (HPLC-MS/MS) was compared with that measured by microparticle
enzyme immunoassay (MEIA) in 30 renal transplant recipients.
Results: Whole blood tacrolimus concentrations measured by HPLC-MS/MS were significantly lower than
those measured by MEIA, with a median difference (interquartile range, IQR) of –0.40 +g/L (2.03 +g/L) (p <
0.0005). MEIA overestimated tacrolimus concentrations by a median (IQR) of 5.04% (19.5%). There was
good correlation between the two methods (r = 0.94; p < 0.0005). The Passing-Bablok regression equation
was: HPLC-MS/MS (+g/L) = 0.96 (95% confidence interval, CI, 0.91–1.00) = MEIA (+g/L) – 0.02 (95% CI,
–0.40–0.46). Bland-Altman analysis showed that the 95% limits of agreement were 2.98 to –4.10 +g/L. The
12-hour area under the concentration curve (AUC12) of tacrolimus derived using the two-point sampling equation
with tacrolimus concentrations measured by HPLC-MS/MS was compared with that measured by MEIA. The
AUC12 values calculated by the two methods were highly correlated (r = 0.90; p < 0.0005). The mean difference
between the AUC12 values was 3.4 ( 11.6 hr.+g/L, and the mean percentage difference was 2.6 ( 11.4%, both
of which were not statistically significant.
Conclusion: For tacrolimus concentrations within the recommended therapeutic range, the concentration
measured by HPLC-MS/MS was statistically significantly lower than that measured by MEIA, but the difference
was not clinically significant. Introduction of the more specific HPLC-MS/MS method does not require
adjustment in the recommended tacrolimus trough concentration or the AUC12 level estimated by our abbreviated
regression equation. [Hong Kong J Nephrol 2005;7(2):65–9]
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INTRODUCTION
Tacrolimus is a potent immunosuppressive agent used
in solid organ transplantation. It has a relatively narrow
therapeutic index [1]. The correlation of dosage to its
blood concentration is poor as a result of variability in
pharmacokinetic parameters among patients [2]. A
consensus has been made that therapeutic monitoring
of whole blood tacrolimus concentration at steady state
is required in view of its dose-related efficacy and
toxicity, narrow therapeutic index, possible cytochrome
P450 mediated drug interactions, and considerable
interpatient variability in its pharmacokinetics [3].
Microparticle enzyme immunoassay (MEIA) has been
commonly used for the measurement of tacrolimus
concentrations in blood as the instrument required is
not very expensive and can be found routinely in clinical
laboratories [4]. However, MEIA uses an anti-
tacrolimus monoclonal antibody that recognizes not
only the parent drug but also several of its metabolites.
Previous studies have demonstrated that this may lead
to overestimation of drug concentration when compared
with a method that is specific for the parent drug [4,5].
High performance liquid chromatography (HPLC)
tandem mass spectrometry (MS/MS) is a sensitive and
specific method for measuring whole blood tacrolimus
concentrations [6]. HPLC-MS/MS has recently been
introduced into hospitals in Hong Kong to replace the
less specific MEIA. However, our past clinical
experience with tacrolimus in renal transplant recipients
has been based on tacrolimus levels measured by MEIA.
To determine if the change in assaying method would
affect our recommended drug dosages for renal
transplant recipients, we compared the results obtained
by the new HPLC-MS/MS method against the
previously established MEIA assay results in the
clinical setting of a group of stable renal transplant
recipients in our center. We examined whether the
change in measurement methods would affect the
clinical management of these patients, especially
regarding whether or not there is a need to develop an
assay-specific target blood tacrolimus concentration
range in the maintenance immunosuppressive therapy
of renal transplant recipients.
METHODS
Thirty renal transplant recipients receiving tacrolimus
were recruited into the study. Their standard immu-
nosuppressive regimen included tacrolimus, pred-
nisolone (7.5 mg/day) and azathioprine (1.5 mg/kg).
To compare the analytical performance of the two assay
methods, 134 blood samples from these patients were
collected by venipuncture and sent to the laboratory in
ethylenediaminetetraacetic acid (EDTA) tubes. The
whole blood tacrolimus concentrations of each blood
sample were measured by both MEIA and HPLC-MS/
MS.
To compare the effects of the two analytical methods
on clinical management, 50 pairs of 2-hour post-dose
(C2) and 4-hour post-dose (C4) whole blood tacrolimus
concentrations from the recruited patients were used.
Estimation of the 12-hour area under the concentration
curve (AUC12) for tacrolimus was done by using a two-
point sampling method with the equation, AUC12 =
16.2 + 2.4 = C2 + 5.9 = C4, that was previously validated
by our group using tacrolimus concentrations as
measured by MEIA [7]. The AUC12 derived from
tacrolimus concentrations measured by HPLC-MS/MS
using the same equation was then compared with the
AUC12 derived from tacrolimus concentrations
measured by MEIA.
MEIA
MEIA was performed on an IMx System analyzer
according to the manufacturer’s instructions (IMx
Tacrolimus II assay; Abbott Diagnostics, Abbott Park,
IL, USA). In short, a whole blood sample was extracted
with a precipitation reagent and centrifuged. Tacrolimus
in the supernatant competed with tacrolimus-alkaline
phosphatase conjugate for antibodies coated on
microparticles. An aliquot of the reaction mixture
containing the tacrolimus or conjugate bound
microparticles was transferred to a glass fiber matrix;
the microparticles bind irreversibly to the glass fiber
matrix. The matrix was washed to remove unbound
materials. A fluorogenic substrate for alkaline phos-
phatase was added to the matrix and the fluorescent
product was measured by the optical assembly. The rate
of fluorescence production is inversely related to the
concentration of tacrolimus in the test sample. Between-
run coefficients of variation were 4.2% at 19.7 +g/L and
9.7% at 6.2 +g/L. The limit of detection was 1.5 +g/L.
HPLC-MS/MS
The HPLC-MS/MS method was performed on the
Agilent 1100 HPLC system (Agilent Technologies Inc,
Palo Alto, CA, USA) equipped with the Sciex API 2000
MS/MS detector (Applied Biosystems, Foster City, CA,
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USA). For sample preparation, 40 +L of calibrators,
quality control or patient samples (EDTA whole blood)
were vortex-mixed for 30 seconds with 140 +L of a
protein precipitation solution containing ascomycin
and zinc sulfate in methanol. After centrifugation for
5 minutes at 17,000g, the supernatants were dispensed
into disposable sample vials and then placed into the
auto-sampler for injection into the system. To separate
tacrolimus and ascomycin from matrix interference
prior to MS/MS analysis, 40 +L of supernatant was
injected into a DASHTM HyPURITY C18 column
(20 mm = 2.1 mm; 5 +m) (Thermo Electron Corp,
Bellefonte, PA, USA) maintained at 50$C inside the
column oven. The column was washed for 30 seconds
(isocratic flow rate, 900 +L/min) with a mixture of
methanol and 0.1% formic acid in 2 mM ammonium
acetate (50:50, by volume). Both tacrolimus and
ascomycin remained in the C18 column. The matrix
interference in the mobile phase was diverted to waste.
Thereafter, the mobile phase was changed to 100%
methanol (flow rate, 350 +L/min). Both tacrolimus and
ascomycin were eluted into the detector. MS/MS
analysis was performed in multiple reactions
monitoring mode using the following transactions:
m/z809.5A756.5 for ascomycin, and m/z821.6A
768.5 for tacrolimus, with a dwell time of 40 ms/
channel. The column was reconditioned with the 50%
methanol solution for 1 minute before the next injection.
The injection-to-injection cycle time was 4 minutes.
System control and data acquisition were performed
using Analyst 1.2 software (Applied Biosystems/MDS
Sciex) for automated data processing. Tacrolimus/
ascomycin peak area ratios for the calibrators, quality
control samples and patient samples were calculated.
The calibration curve was constructed using linear least
squares regression with 1/= weighting. The between-
batch coefficients of variation for HPLC-MS/MS were
3.2–5.2% for three levels of quality control samples
(mean concentrations: 4.3, 10.0 and 22.6 +g/L). The
mean recovery was 96.4%. The detection limit at a
signal-to-noise ratio of 3 was 0.5 +g/L, and the method
was linear up to 160 +g/L.
Statistical analysis
MedCalc statistical package version 7 (MedCalc
Software, Mariakerke, Belgium) was used for data
analysis. The Kolmogorov-Smirnov test was used for
Gaussian distribution testing. Data were expressed as
mean ( standard deviation or median (interquartile
range, IQR) where appropriate. The Wilcoxon test was
used to test for significance of difference between the
two assays. To analyze the agreement between the two
assays, Passing-Bablok regression analysis, the Bland-
Altman method [8], and Spearman’s rank correlation
were used. A p value of less than 0.05 was considered
to be statistically significant.
RESULTS
Of the 30 stable renal transplant recipients recruited,
16 (53%) were male. The mean age was 42.6 ( 11.4
years. All patients had normal liver function. Whole
blood tacrolimus concentrations were measured at a
median of 13.5 months (IQR, 0.1–88.9 months)
post-transplant as part of routine clinical care. The
number of samples taken from each patient ranged from
1 to 14.
For the evaluation of the analytical performance of
the two assays, the median blood tacrolimus con-
centrations measured by HPLC-MS/MS and MEIA
were 9.75 (7.08) +g/L and 10.30 (8.08) +g/L, respec-
tively. Blood tacrolimus concentrations measured by
HPLC-MS/MS were found to be significantly lower
than that measured by MEIA, with a median difference
of –0.40 (2.03) +g/L (p < 0.0005). Percentage difference
(%diff) was calculated as the difference between the
two methods as a percentage of the HPLC-MS/MS
value. The median %diff was 5.04% (19.5%). The
relationship between tacrolimus concentrations as
measured by MEIA and HPLC-MS/MS is shown in
Figure 1. There was a good correlation between the
two methods (r = 0.94; p < 0.0005). The Passing-Bablok
regression equation was: HPLC-MS/MS (+g/L) =
0.96 (95% confidence interval, CI, 0.91–1.00) = MEIA
(+g/L) – 0.02 (95% CI, –0.40–0.46). A Bland-Altman
analysis was also performed and the 95% limits of
agreement were calculated [7]. The differences between
the tacrolimus concentrations measured by HPLC-MS/
MS and MEIA were plotted against their average values
(Figure 2). The 95% limits of agreement were 2.98 to
–4.10 +g/L. Ninety percent of the patients had an
absolute difference of less than 3.1 +g/L. Thus, in our
center, blood tacrolimus concentrations measured by
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Figure 1. Passing-Bablok regression plot of tacrolimus concen-
trations as measured by MEIA and HPLC-MS/MS in renal trans-
plant recipients.
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the new HPLC-MS/MS tended to be lower than the
previously used MEIA.
To evaluate the effects of the two assays on clinical
management, the AUC12 values calculated by our
previously validated equation using tacrolimus con-
centrations measured by the two methods were com-
pared in 50 paired samples. The medians of AUC12 for
tacrolimus measured by HPLC-MS/MS and MEIA
were 86.9 (35.0) hr.+g/L and 92.2 (41.4) hr.+g/L,
respectively. The AUC12 values derived from tacrolimus
concentrations measured by the two methods were
highly correlated (r = 0.90; p < 0.0005). The mean
difference between the AUC12 values was 3.4 ( 11.6
hr.+g/L, which was not statistically significant (p =
0.059). The mean %diff calculated as the mean of the
difference between the two methods as a percentage of
AUC12-MEIA was 2.6 (  11.4%, which was not
statistically significant (p = 0.107).
DISCUSSION
HPLC-MS/MS is a sensitive and specific method for
measuring tacrolimus concentration, but its use has
been limited by availability and high instrumental
cost. Immunoassays such as MEIA provide a simple
and convenient alternative for measuring tacrolimus
concentration [4]. However, these assays have the
disadvantage of the anti-tacrolimus monoclonal
antibody exhibiting substantial cross-reactivity with
tacrolimus metabolites, in particular 31-O-demethyl
(M-II), 15-O-demethyl (M-III) and 15,31-O-didemethyl
(M-V)[9]. Several groups have reported higher
tacrolimus concentrations in patient samples measured
by immunoassays compared with specific methods such
as HPLC-MS/MS [4,5,10]. This discrepancy could be
caused by the presence of cross-reacting tacrolimus
metabolites in the patient specimens that may or may
not be immunosuppressive. In our study, we also
confirmed the overestimation of whole blood tacroli-
mus concentration by MEIA. The median difference
between the two assays was 0.40 +g/L, corresponding
to a median overestimation of 5.04% by MEIA.
However, the correlation between the two assays was
excellent (r = 0.94).
The reported overestimation of tacrolimus con-
centrations by immunoassays in renal transplant recip-
ients in other studies has ranged from 18% to 48%
[4,10], which is much greater than our current finding.
It has been reported that for cyclosporine drug level
monitoring, the discrepancy between HPLC-MS/MS
and immunoassays is greater when trough level samples
are used instead of C2 level samples [11]. The reason
might be due to the different proportions of parent
cyclosporine and metabolites at these two time points.
At the trough level, the relative concentration between
the parent drug and its cross-reacting metabolites is
higher when compared with that at C2, thus resulting
in a larger discrepancy [11]. We believe that our smaller
observed discrepancy between the two assaying
methods compared with previously published results
is due to the fact that the majority of our samples were
collected at C2 or C4, when there is a lower relative
concentration between the parent drug and its cross-
reacting metabolites.
The specific HPLC-MS/MS assay of tacrolimus
concentration has been recently introduced in Hong
Kong to replace the immunoassay methods. The change
in assay method for measuring tacrolimus drug
concentration might affect our recommended drug
concentration for our renal transplant recipients. In this
study, we demonstrated that the median difference in
tacrolimus concentration measured by the two methods
was only 0.4 +g/L, with a %diff of 5.04%. Although
the difference was statistically significant, it was not
clinically significant and did not affect our daily clinical
management. We believe that a change in the
recommended drug concentration for maintenance
tacrolimus therapy will not be required. However,
clinicians should be aware that for tacrolimus con-
centrations lying at the extremes of distribution, the
discrepancy between the two assays would be much
greater and might be of clinical significance. More
aggressive dosage adjustment of tacrolimus to minimize
tacrolimus-related adverse effects might be required,
especially at the time of early post-kidney transplant.
The usefulness of using tacrolimus trough levels
in differentiating graft rejection episodes from
nephrotoxicity has been questioned [12]. The use of
AUC for tacrolimus has been suggested as a more
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Figure 2. Bland-Altman analysis of the difference between HPLC-
MS/MS and MEIA. The mean difference was –0.56 +g/L; the
standard deviation was 1.77 +g/L; 95% of the difference was within
the range of –4.10 to 2.98 +g/L. The mean ( 2 standard deviation
lines have been plotted for reference.
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precise model for tacrolimus monitoring after renal
transplant [13]. A dosing regimen with a target AUC12
of approximately 100 +g/L has been advised in renal
transplant recipients to minimize adverse events [13].
Traditionally, AUC is determined from six or more
concentration-time data points. Its routine clinical use
is limited by the need for multiple blood samples and
drug measurements, which causes inconvenience to
both patients and medical personnel. Instead, our group
has derived and validated a two-point sampling method
using C2 and C4 tacrolimus concentrations measured
by immunoassay to estimate the AUC12 as the
tacrolimus monitoring strategy for our renal transplant
recipients [7]. In our center, we have been using this
abbreviated regression equation to guide our tacrolimus
dosing, aiming for AUC12 of 100 hr.+g/L at 3 months
post-kidney transplant, with good outcome. However,
the change in the tacrolimus assay method may affect
our dosing recommendation using the abbreviated
regression equation. In this study, we estimated the
AUC12s for tacrolimus of 50 paired samples by the
equation using tacrolimus concentrations measured by
HPLC-MS/MS and MEIA respectively. We found that
the AUC12s calculated with tacrolimus levels measured
by the two methods were highly correlated (r = 0.90;
p < 0.0005), and the mean difference between them
was statistically insignificant. We believe that for
maintenance therapy in renal transplant recipients,
clinicians should continue to titrate the dosage of
tacrolimus using the same abbreviated equation calcu-
lated with tacrolimus concentrations as measured by
HPLC-MS/MS, targeting at AUC12 of approximately
100 hr.+g/L at 3 months post-transplant. However,
further validation of the equation by using tacrolimus
concentrations measured by HPLC-MS/MS will be
required in future.
In conclusion, blood tacrolimus concentrations
measured by HPLC-MS/MS were significantly lower
than those measured by MEIA. Apparently, for
tacrolimus concentrations within the therapeutic range,
the magnitude of the difference between tacrolimus
concentrations measured by HPLC-MS/MS and MEIA
II was not clinically significant. The introduction of
the more specific HPLC-MS/MS assay method does
not require adjustment in the recommended tacrolimus
trough concentration or the AUC12 level as estimated
by our abbreviated regression equation for maintenance
immunosuppressive therapy. However, care should be
taken when interpreting tacrolimus concentrations at
the extremes of distribution to avoid tacrolimus-related
adverse effects. Further longitudinal study will be
required to determine the clinical importance of the
observed differences between the new and old assay
methods in our renal transplant population.
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